NHS Genomic Medicine Service - Most Suitable Provider Process
Overview
Summary, notice description and lot information
The NHS Genomic Medicine Service (NHS GMS) tender, managed by NHS England, is a significant procurement process aiming to enhance health services across various regions in the United Kingdom. With an estimated total contract value of £5,175,000,000, the services are anticipated to commence on 1st April 2026 and could extend until 31st March 3036. The procurement is segmented into seven distinct Lots, targeting geographic areas like North-West, North-East and Yorkshire, Central and South, with NHS organisations positioned as potential providers.
This notice reflects the intention to award under the Provider Selection Regime, highlighting key dates such as the standstill period resulting from the publication on 23rd October 2025 and a deadline for representations by 4th November 2025. The procurement is conducted through a limited procedure, bypassing prior competition calls. This tender presents substantial opportunities for existing NHS organisations equipped to integrate genomic medicine service functions.
It is designed for entities that can demonstrate advanced capabilities in genomic testing, clinical pathways for cancer and rare diseases, and integration of data infrastructure. By enabling expansion in genomic innovation and service delivery, the tender is particularly suited for large-scale NHS suppliers ready to collaborate and leverage existing clinical governance structures. Companies with a focus on integrating new genomic technologies and improving healthcare equity will find immense potential for growth and service improvement in partnership with NHS England through this procurement endeavour.
This is a notice of intention to make an award in respect of the NHS Genomic Medicine Service pursuant to the Most Suitable Provider (MSP) Process for the NHS Genomic Medicine Service (NHS GMS). For the avoidance of doubt, this is an intention to award notice. A notice of the confirmation of the award of each contract will be issued once they are signed.
Pursuant to the NHS GMS contracts, provider are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is PS5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is PS5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is PS5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is PS5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is PS5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is PS5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People - workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is PS5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Procurement Classification
Notice type, method, and CPV codes
Contract Values
Financial information and value estimates
Contract duration information not available.
Key Dates
Publication, submission, and award timeline
Notice Status
Current status of tender, lots, awards, and contracts
Contracting Authority
Buyer organisation and contact details
Awarded Supplier
Supplier who was awarded this contract
Documents & Links
External resources and data downloads
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector.
Need help with your tender submission?
Our expert team can help you prepare a winning bid. Get professional support from CareSync Experts.
Get in touch with our team at Care Sync Experts today for a consultation.
Email: hello@caresyncexperts.co.uk
Phone: 0333 577 0877
Contact UsBidding for contracts like this
Other tenders in Leeds
- Radiotherapy in Leeds
- Radiotherapy in Leeds
- Specialised Commissioning Acute Services- East of England in Leeds
- Specialised Commissioning Retained Mental Health, Learning Disability and Autism Services (MHLDA)- The North West in Leeds
- Specialised Commissioning Acute Contract- North West in Leeds
- Specialised Commissioning Retained Mental Health, Learning Disability and Autism Services (MHLDA)- South West in Leeds